Literature DB >> 18400803

Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study.

Mette Nørgaard1, Lars Pedersen, Mette Gislum, Rune Erichsen, Kirstine Kobberøe Søgaard, Henrik Carl Schønheyder, Henrik Toft Sørensen.   

Abstract

OBJECTIVES: Fluconazole is widely used for the treatment of candidiasis. Although the drug is also prescribed to pregnant women, data on the safety of use of fluconazole during pregnancy are limited. We examined the association between the maternal use of fluconazole during pregnancy and the risk of congenital malformations. PATIENTS AND METHODS: In this population-based cohort study in Northern Denmark, we included 1079 women who had a live birth or a stillbirth after the 20th week of gestation and who redeemed at least one prescription for fluconazole during the first trimester. The reference cohort comprised 170 453 pregnant women who redeemed no fluconazole prescription during pregnancy. The women were identified through the Danish Medical Birth Registry. Data on drug use, birth outcome and covariates were extracted from population-based healthcare databases. We used logistic regression to estimate the prevalence odds ratio (POR) for congenital malformations after fluconazole exposure, while adjusting for maternal smoking, parity, maternal age and concurrent prescriptions for antiepileptics or antidiabetics.
RESULTS: Among 1079 women who filled a fluconazole prescription during the first trimester, 797 (74%) received a total of 150 mg of fluconazole, 235 (22%) received 300 mg of fluconazole, 24 (2%) received 350 mg of fluconazole and 23 (2%) received 600 mg of fluconazole. These women gave birth to 44 (4.1%) children with congenital malformations. The 170 453 women without fluconazole prescriptions gave birth to 6152 (3.6%) children with congenital malformations. For congenital malformations overall, the adjusted POR associated with the first-trimester fluconazole use was 1.0 (95% confidence interval: 0.8-1.4).
CONCLUSIONS: We found no overall increased risk of congenital malformations after exposure to short-course treatment with fluconazole in early pregnancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400803     DOI: 10.1093/jac/dkn157

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Severe systemic candidiasis following immunomodulation therapy in in vitro fertilisation-embryo transfer (IVF-ET).

Authors:  Folasade Akhanoba; Jane MacDougall; Raj Mathur; Wassim Hassan
Journal:  BMJ Case Rep       Date:  2014-03-31

Review 2.  Vaginal yeast infections during pregnancy.

Authors:  Derrick Soong; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2009-03       Impact factor: 3.275

3.  PURLs: Yeast infection in pregnancy? Think twice about fluconazole.

Authors:  Amir Barzin; Anne Mounsey
Journal:  J Fam Pract       Date:  2016-09       Impact factor: 0.493

4.  Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management.

Authors:  Katelyn A Pastick; Elizabeth Nalintya; Lillian Tugume; Kenneth Ssebambulidde; Nicole Stephens; Emily E Evans; Jane Frances Ndyetukira; Edwin Nuwagira; Caleb Skipper; Conrad Muzoora; David B Meya; Joshua Rhein; David R Boulware; Radha Rajasingham
Journal:  Med Mycol       Date:  2020-04-01       Impact factor: 4.076

5.  Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.

Authors:  Anick Bérard; Odile Sheehy; Jin-Ping Zhao; Jessica Gorgui; Sasha Bernatsky; Cristiano Soares de Moura; Michal Abrahamowicz
Journal:  CMAJ       Date:  2019-02-19       Impact factor: 8.262

6.  Anti-infective use in children and pregnancy: current deficiencies and future challenges.

Authors:  Amanda Gwee; Noel Cranswick
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

7.  Vulvovaginal candidiasis in pregnancy.

Authors:  T J Aguin; J D Sobel
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

8.  Fluconazole exposure during pregnancy.

Authors:  Yusuf Cem Kaplan; Gideon Koren; Pina Bozzo
Journal:  Can Fam Physician       Date:  2015-08       Impact factor: 3.275

9.  Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: A systematic review and meta-analysis.

Authors:  Dan Liu; Chuan Zhang; Lin Wu; Li Zhang; Lingli Zhang
Journal:  Int J Gynaecol Obstet       Date:  2019-11-05       Impact factor: 3.561

10.  Existing data sources for clinical epidemiology: Aarhus University Prescription Database.

Authors:  Vera Ehrenstein; Sussie Antonsen; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-12-02       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.